Pathology Associated with AAV Mediated Expression of Beta Amyloid or C100 in Adult Mouse Hippocampus and Cerebellum

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Drummond, Eleanor S ^a   Muhling, Jill ^a   Martins, Ralph N ^a,b   Wijaya, Linda K ^b   Ehlert, Erich M ^c   Harvey, Alan R ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b EDITH COWAN UNIVERSITY   (Australia)

^c NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E; BRAIN PROTEIN; C100 PROTEIN; CLUSTERIN; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G; MESSENGER RNA; PARVOVIRUS VECTOR; PRESENILIN 1; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ADULT ANIMAL; ALZHEIMER DISEASE; AMYLOID BETA PROTEIN[1-40] GENE; AMYLOID BETA PROTEIN[1-42] GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOLIPOPROTEIN E GENE; ARTICLE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; BRAIN REGION; C100 GENE; CELL DENSITY; CEREBELLUM; CLUSTERIN GENE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE EXPRESSION REGULATION; GLIOSIS; HIPPOCAMPUS; MALE; MOUSE; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PRESENILIN 1 GENE; PROTEIN EXPRESSION; SYNAPTOPHYSIN GENE; TRANSGENE;

AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE; CEREBELLUM; DEPENDOVIRUS; GENETIC VECTORS; HELA CELLS; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; PC12 CELLS;

EID: 84874831016     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059166     Document Type: Article

References (80)

1. McGowan E, Pickford F, Kim J, Onstead L, Eriksen J, et al. (2005) Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47: 191-199.
2. Lawlor P, Bland R, Das P, Price R, Holloway V, et al. (2007) Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Molecular Neurodegeneration 2: 11.
3. Lemere CA, Masliah E, (2010) Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 6: 108-119.
4. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, et al. (2008) Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7: 779-786.
5. Siemers ER, Friedrich S, Dean RA, Gonzales CR, Farlow MR, et al. (2010) Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol 33: 67-73.
6. Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, et al. (2009) A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 66: 48-54.
7. Rebeck GW, Hoe HS, Moussa CE, (2010) Beta-amyloid1-42 gene transfer model exhibits intraneuronal amyloid, gliosis, tau phosphorylation, and neuronal loss. J Biol Chem 285: 7440-7446.
8. Nikolaev A, McLaughlin T, O'Leary DD, Tessier-Lavigne M, (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457: 981-989.
9. Dewachter I, Reverse D, Caluwaerts N, Ris L, Kuiperi C, et al. (2002) Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice. Journal of Neuroscience 22: 3445-3453.
10. Yu H, Saura C, Choi S, Sun L, Yang X, et al. (2001) APP processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron 31: 713-726.
11. Cao X, Südhof T, (2001) A transcriptionally active complex of APP with Fe65 and histone acetyltransferase Tip60. Science 293: 115-120.
12. Hiltunen M, van Groen T, Jolkkonen J, (2009) Functional roles of amyloid-beta protein precursor and amyloid-beta peptides: evidence from experimental studies. J Alzheimers Dis 18: 401-412.
13. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, et al. (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264: 1336-1340.
14. Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, et al. (1997) Amyloid precursor protein processing and A beta42 deposition in a transgenic mouse model of Alzheimer disease. Proc Natl Acad Sci U S A 94: 1550-1555.
15. Mason MR, Ehlert EM, Eggers R, Pool CW, Hermening S, et al. (2010) Comparison of AAV serotypes for gene delivery to dorsal root ganglion neurons. Mol Ther 18: 715-724.
16. Schmidt SD, Nixon RA, Mathews PM, (2005) ELISA method for measurement of amyloid-beta levels. Methods Mol Biol 299: 279-297.
17. Bartlett JS, Samulski RJ, McCown TJ, (1998) Selective and rapid uptake of adeno-associated virus type 2 in brain. Hum Gene Ther 9: 1181-1186.
18. Passini MA, Dodge JC, Bu J, Yang W, Zhao Q, et al. (2006) Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis. J Neurosci 26: 1334-1342.
19. Kaspar BK, Erickson D, Schaffer D, Hinh L, Gage FH, et al. (2002) Targeted retrograde gene delivery for neuronal protection. Mol Ther 5: 50-56.
20. Imai Y, Ibata I, Ito D, Ohsawa K, Kohsaka S, (1996) A novel gene iba1 in the major histocompatibility complex class III region encoding an EF hand protein expressed in a monocytic lineage. Biochem Biophys Res Commun 224: 855-862.
21. DeMattos R, Cirrito J, Parsadanian M, May P, O'Dell M, et al. (2004) ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41: 193-202.
22. Masliah E, Terry RD, DeTeresa RM, Hansen LA, (1989) Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci Lett 103: 234-239.
23. Borghi R, Piccini A, Barini E, Cirmena G, Guglielmotto M, et al. (2010) Upregulation of presenilin 1 in brains of sporadic, late-onset Alzheimer's disease. J Alzheimers Dis 22: 771-775.
24. Yamagata K, Urakami K, Ikeda K, Ji Y, Adachi Y, et al. (2001) High expression of apolipoprotein E mRNA in the brains with sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 12: 57-62.
25. Lidstrom AM, Bogdanovic N, Hesse C, Volkman I, Davidsson P, et al. (1998) Clusterin (apolipoprotein J) protein levels are increased in hippocampus and in frontal cortex in Alzheimer's disease. Exp Neurol 154: 511-521.
26. Shaffer LM, Dority MD, Gupta-Bansal R, Frederickson RC, Younkin SG, et al. (1995) Amyloid beta protein (A beta) removal by neuroglial cells in culture. Neurobiol Aging 16: 737-745.
27. Meyer-Luehmann M, Spires-Jones TL, Prada C, Garcia-Alloza M, de Calignon A, et al. (2008) Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature 451: 720-724.
28. Weldon DT, Rogers SD, Ghilardi JR, Finke MP, Cleary JP, et al. (1998) Fibrillar beta-amyloid induces microglial phagocytosis, expression of inducible nitric oxide synthase, and loss of a select population of neurons in the rat CNS in vivo. J Neurosci 18: 2161-2173.
29. Passos GF, Figueiredo CP, Prediger RD, Silva KA, Siqueira JM, et al. (2010) Involvement of phosphoinositide 3-kinase gamma in the neuro-inflammatory response and cognitive impairments induced by beta-amyloid 1-40 peptide in mice. Brain Behav Immun 24: 493-501.
30. Jantaratnotai N, Ryu JK, Kim SU, McLarnon JG, (2003) Amyloid beta peptide-induced corpus callosum damage and glial activation in vivo. Neuroreport 14: 1429-1433.
31. Radde R, Bolmont T, Kaeser SA, Coomaraswamy J, Lindau D, et al. (2006) Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 7: 940-946.
32. Oakley H, Cole SL, Logan S, Maus E, Shao P, et al. (2006) Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci 26: 10129-10140.
33. Bales K, Verina T, Cummins D, Du Y, Dodel R, et al. (1999) Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 96: 15233-15238.
34. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, et al. (1999) Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
35. Weiner HL, Lemere CA, Maron R, Spooner ET, Grenfell TJ, et al. (2000) Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease. Annals of Neurology 48: 567-579.
36. Seitz RJ, Heininger K, Schwendemann G, Toyka KV, Wechsler W, (1985) The mouse blood-brain barrier and blood-nerve barrier for IgG: a tracer study by use of the avidin-biotin system. Acta Neuropathol 68: 15-21.
37. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, et al. (2004) Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 10: 1366-1373.
38. Marchi N, Teng Q, Ghosh C, Fan Q, Nguyen MT, et al. (2010) Blood-brain barrier damage, but not parenchymal white blood cells, is a hallmark of seizure activity. Brain Res 1353: 176-186.
39. Nicaise C, Mitrecic D, Demetter P, De Decker R, Authelet M, et al. (2009) Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res 1301: 152-162.
40. Baker EA, Tian Y, Adler S, Verbalis JG, (2000) Blood-brain barrier disruption and complement activation in the brain following rapid correction of chronic hyponatremia. Exp Neurol 165: 221-230.
41. Fullerton SM, Shirman GA, Strittmatter WJ, Matthew WD, (2001) Impairment of the blood-nerve and blood-brain barriers in apolipoprotein e knockout mice. Exp Neurol 169: 13-22.
42. Farkas IG, Czigner A, Farkas E, Dobo E, Soos K, et al. (2003) Beta-amyloid peptide-induced blood-brain barrier disruption facilitates T-cell entry into the rat brain. Acta Histochem 105: 115-125.
43. Ito D, Imai Y, Ohsawa K, Nakajima K, Fukuuchi Y, et al. (1998) Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res Mol Brain Res 57: 1-9.
44. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, et al. (2008) Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 14: 681-687.
45. Kalaria RN, (1997) Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer's disease. Ann N Y Acad Sci 826: 263-271.
46. Donahue JE, Johanson CE, (2008) Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J Neuropathol Exp Neurol 67: 261-270.
47. Jancso G, Domoki F, Santha P, Varga J, Fischer J, et al. (1998) Beta-amyloid (1-42) peptide impairs blood-brain barrier function after intracarotid infusion in rats. Neurosci Lett 253: 139-141.
48. Su GC, Arendash GW, Kalaria RN, Bjugstad KB, Mullan M, (1999) Intravascular infusions of soluble beta-amyloid compromise the blood-brain barrier, activate CNS glial cells and induce peripheral hemorrhage. Brain Res 818: 105-117.
49. Pihlaja R, Koistinaho J, Malm T, Sikkila H, Vainio S, et al. (2008) Transplanted astrocytes internalize deposited beta-amyloid peptides in a transgenic mouse model of Alzheimer's disease. Glia 56: 154-163.
50. Canning DR, McKeon RJ, DeWitt DA, Perry G, Wujek JR, et al. (1993) beta-Amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp Neurol 124: 289-298.
51. Pike CJ, Cummings BJ, Monzavi R, Cotman CW, (1994) Beta-amyloid-induced changes in cultured astrocytes parallel reactive astrocytosis associated with senile plaques in Alzheimer's disease. Neuroscience 63: 517-531.
52. Kamphuis W, Mamber C, Moeton M, Kooijman L, Sluijs JA, et al. (2012) GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease. PLoS One 7: e42823.
53. Rodriguez JJ, Olabarria M, Chvatal A, Verkhratsky A, (2009) Astroglia in dementia and Alzheimer's disease. Cell Death Differ 16: 378-385.
54. McGowan E, Eriksen J, Hutton M, (2006) A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 22: 281-289.
55. Jaworski T, Dewachter I, Lechat B, Croes S, Termont A, et al. (2009) AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice. PLoS One 4: e7280.
56. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, et al. (2005) Tau suppression in a neurodegenerative mouse model improves memory function. Science 309: 476-481.
57. Ramsden M, Kotilinek L, Forster C, Paulson J, McGowan E, et al. (2005) Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci 25: 10637-10647.
58. Tomiyama T, Matsuyama S, Iso H, Umeda T, Takuma H, et al. (2010) A mouse model of amyloid beta oligomers: their contribution to synaptic alteration, abnormal tau phosphorylation, glial activation, and neuronal loss in vivo. J Neurosci 30: 4845-4856.
59. Ishibashi K, Tomiyama T, Nishitsuji K, Hara M, Mori H, (2006) Absence of synaptophysin near cortical neurons containing oligomer Abeta in Alzheimer's disease brain. J Neurosci Res 84: 632-636.
60. Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, et al. (2009) Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life. Neurobiol Dis 36: 293-302.
61. Buttini M, Masliah E, Barbour R, Grajeda H, Motter R, et al. (2005) Beta-amyloid immunotherapy prevents synaptic degeneration in a mouse model of Alzheimer's disease. J Neurosci 25: 9096-9101.
62. Jacobsen JS, Wu CC, Redwine JM, Comery TA, Arias R, et al. (2006) Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103: 5161-5166.
63. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT, (1997) APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J Neuropathol Exp Neurol 56: 965-973.
64. Bolmont T, Haiss F, Eicke D, Radde R, Mathis CA, et al. (2008) Dynamics of the microglial/amyloid interaction indicate a role in plaque maintenance. J Neurosci 28: 4283-4292.
65. Mandrekar S, Jiang Q, Lee CY, Koenigsknecht-Talboo J, Holtzman DM, et al. (2009) Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci 29: 4252-4262.
66. Chung H, Brazil M, Soe T, Maxfield F, (1999) Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. Journal of Biological Chemistry 274: 32301-32308.
67. Paresce DM, Chung H, Maxfield FR, (1997) Slow degradation of aggregates of the Alzheimer's disease amyloid beta-protein by microglial cells. J Biol Chem 272: 29390-29397.
68. El Khoury J, Toft M, Hickman SE, Means TK, Terada K, et al. (2007) Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med 13: 432-438.
69. Vigo-Pelfrey C, Lee D, Keim P, Lieberburg I, Schenk D, (1993) Characterization of beta-amyloid peptide from human cerebrospinal fluid. Journal of Neurochemistry 61: 1965-1968.
70. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, et al. (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43: 333-344.
71. Cribbs DH, Chen LS, Bende SM, LaFerla FM, (1996) Widespread neuronal expression of the presenilin-1 early-onset Alzheimer's disease gene in the murine brain. Am J Pathol 148: 1797-1806.
72. Mita S, Schon EA, Herbert J, (1989) Widespread expression of amyloid beta-protein precursor gene in rat brain. Am J Pathol 134: 1253-1261.
73. Joachim CL, Morris JH, Selkoe DJ, (1989) Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 135: 309-319.
74. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC, (2002) Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol 59: 1381-1389.
75. Hashimoto M, Bogdanovic N, Volkmann I, Aoki M, Winblad B, et al. (2010) Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Abeta42 and Alzheimer's disease neuropathology. Acta Neuropathol 119: 543-554.
76. Du J, Sun B, Chen K, Zhang L, Liu S, et al. (2009) Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease. PLoS One 4: e5530.
77. Causevic M, Farooq U, Lovestone S, Killick R, (2010) beta-Amyloid precursor protein and tau protein levels are differently regulated in human cerebellum compared to brain regions vulnerable to Alzheimer's type neurodegeneration. Neurosci Lett 485: 162-166.
78. Caccamo A, Oddo S, Sugarman MC, Akbari Y, LaFerla FM, (2005) Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging 26: 645-654.
79. Maruyama K, Tagawa K, Kawamura Y, Asada H, Ishiura S, et al. (1995) Secretion of Alzheimer beta/A4 protein (1-40) and intracellular retention of beta/A4 protein (1-42) in transfected COS cells. Biochem Biophys Res Commun 207: 971-977.
80. Magrane J, Smith R, Walsh K, Querfurth H, (2004) Heat shock protein 70 participates in the neuroprotective response to intracellularly expressed beta-amyloid in neurons. Journal of Neuroscience 24: 1700-1706.